Amedeo Smart

Free Medical Literature Service



Alzheimer's Disease

  Free Subscription

Articles published in
Alzheimers Dement
    November 2021
    Hypothesis: Modulation of microglial phenotype in Alzheimer's disease drives neurodegeneration.
    Alzheimers Dement. 2021 Nov 17. doi: 10.1002/alz.12503.
    >> Share

  2. JIA L, Yang J, Zhu M, Pang Y, et al
    A metabolite panel that differentiates Alzheimer's disease from other dementia types.
    Alzheimers Dement. 2021 Nov 17. doi: 10.1002/alz.12484.
    >> Share

  3. WEINTRAUB S, Karpouzian-Rogers T, Peipert JD, Nowinski C, et al
    ARMADA: Assessing reliable measurement in Alzheimer's disease and cognitive aging project methods.
    Alzheimers Dement. 2021 Nov 17. doi: 10.1002/alz.12497.
    >> Share

  4. JUTKOWITZ E, Halladay C, Tsai J, Hooshyar D, et al
    Prevalence of Alzheimer's disease and related dementias among veterans experiencing housing insecurity.
    Alzheimers Dement. 2021 Nov 10. doi: 10.1002/alz.12476.
    >> Share

  5. HORGUSLUOGLU E, Neff R, Song WM, Wang M, et al
    Integrative metabolomics-genomics approach reveals key metabolic pathways and regulators of Alzheimer's disease.
    Alzheimers Dement. 2021 Nov 10. doi: 10.1002/alz.12468.
    >> Share

  6. BOADA M, Lopez OL, Olazaran J, Nunez L, et al
    Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study.
    Alzheimers Dement. 2021 Nov 2. doi: 10.1002/alz.12477.
    >> Share

    October 2021
  7. TOSUN D, Demir Z, Veitch DP, Weintraub D, et al
    Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum.
    Alzheimers Dement. 2021 Oct 14. doi: 10.1002/alz.12480.
    >> Share

  8. MEYERS EA, Amouyel P, Bovenkamp DE, Carrillo MC, et al
    Commentary: Global Alzheimer's disease and Alzheimer's disease related dementia research funding organizations support and engage the research community throughout the COVID-19 pandemic.
    Alzheimers Dement. 2021 Oct 1. doi: 10.1002/alz.12472.
    >> Share

  9. Alzheimer's Disease Interventions: Implications of therapeutic promises amidst questions and doubts about clinically meaningful outcomes.
    Alzheimers Dement. 2021;17:1591-1594.
    >> Share

    September 2021
  10. FRANZEN S, Smith JE, van den Berg E, Rivera Mindt M, et al
    Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria.
    Alzheimers Dement. 2021 Sep 30. doi: 10.1002/alz.12433.
    >> Share

  11. PICARD C, Nilsson N, Labonte A, Auld D, et al
    Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease.
    Alzheimers Dement. 2021 Sep 29. doi: 10.1002/alz.12442.
    >> Share

  12. JICHA GA, Abner EL, Arnold SE, Carrillo MC, et al
    Committee on High-quality Alzheimer's Disease Studies (CHADS) consensus report.
    Alzheimers Dement. 2021 Sep 29. doi: 10.1002/alz.12461.
    >> Share

  13. CUMMINGS JL, Goldman DP, Simmons-Stern NR, Ponton E, et al
    The costs of developing treatments for Alzheimer's disease: A retrospective exploration.
    Alzheimers Dement. 2021 Sep 28. doi: 10.1002/alz.12450.
    >> Share

  14. VEITCH DP, Weiner MW, Aisen PS, Beckett LA, et al
    Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease.
    Alzheimers Dement. 2021 Sep 28. doi: 10.1002/alz.12422.
    >> Share

  15. WANG C, Wang Z, Xie B, Shi X, et al
    Binaural processing deficit and cognitive impairment in Alzheimer's disease.
    Alzheimers Dement. 2021 Sep 27. doi: 10.1002/alz.12464.
    >> Share

  16. MATTKE S, Hanson M
    Expected wait times for access to a disease-modifying Alzheimer's treatment in the United States.
    Alzheimers Dement. 2021 Sep 27. doi: 10.1002/alz.12470.
    >> Share

  17. PHILLIPS JS, Nitchie FJ 4th, Da Re F, Olm CA, et al
    Rates of longitudinal change in (18) F-flortaucipir PET vary by brain region, cognitive impairment, and age in atypical Alzheimer's disease.
    Alzheimers Dement. 2021 Sep 13. doi: 10.1002/alz.12456.
    >> Share

  18. ZHANG L, Du Rietz E, Kuja-Halkola R, Dobrosavljevic M, et al
    Attention-deficit/hyperactivity disorder and Alzheimer's disease and any dementia: A multi-generation cohort study in Sweden.
    Alzheimers Dement. 2021 Sep 9. doi: 10.1002/alz.12462.
    >> Share

  19. CHATTERJEE P, Pedrini S, Ashton NJ, Tegg M, et al
    Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease.
    Alzheimers Dement. 2021 Sep 8. doi: 10.1002/alz.12447.
    >> Share

  20. MARTERSTECK A, Sridhar J, Coventry C, Weintraub S, et al
    Relationships among tau burden, atrophy, age, and naming in the aphasic variant of Alzheimer's disease.
    Alzheimers Dement. 2021 Sep 8. doi: 10.1002/alz.12445.
    >> Share

  21. LOGSDON AF, Francis KL, Richardson NE, Hu SJ, et al
    Decoding perineuronal net glycan sulfation patterns in the Alzheimer's disease brain.
    Alzheimers Dement. 2021 Sep 5. doi: 10.1002/alz.12451.
    >> Share

  22. MA Y, Yu L, Olah M, Smith R, et al
    Epigenomic features related to microglia are associated with attenuated effect of APOE epsilon4 on Alzheimer's disease risk in humans.
    Alzheimers Dement. 2021 Sep 5. doi: 10.1002/alz.12425.
    >> Share

  23. REN RJ, Huang Q, Xu G, Gu K, et al
    Association between Alzheimer's disease and risk of cancer: A retrospective cohort study in Shanghai, China.
    Alzheimers Dement. 2021 Sep 5. doi: 10.1002/alz.12436.
    >> Share

    August 2021
  24. GHAZARIAN AL, Haim T, Sauma S, Katiyar P, et al
    National Institute on Aging seed funding enables Alzheimer's disease startups to reach key value inflection points.
    Alzheimers Dement. 2021 Aug 10. doi: 10.1002/alz.12392.
    >> Share

  25. WANG Q, Davis PB, Gurney ME, Xu R, et al
    COVID-19 and dementia: Analyses of risk, disparity, and outcomes from electronic health records in the US.
    Alzheimers Dement. 2021;17:1297-1306.
    >> Share

  26. PIERUCCINI-FARIA F, Black SE, Masellis M, Smith EE, et al
    Gait variability across neurodegenerative and cognitive disorders: Results from the Canadian Consortium of Neurodegeneration in Aging (CCNA) and the Gait and Brain Study.
    Alzheimers Dement. 2021;17:1317-1328.
    >> Share

  27. BAUCKNEHT M, Chincarini A, Brendel M, Rominger A, et al
    Associations among education, age, and the dementia with Lewy bodies (DLB) metabolic pattern: A European-DLB consortium project.
    Alzheimers Dement. 2021;17:1277-1286.
    >> Share

  28. GIANATTASIO KZ, Bennett EE, Wei J, Mehrotra ML, et al
    Generalizability of findings from a clinical sample to a community-based sample: A comparison of ADNI and ARIC.
    Alzheimers Dement. 2021;17:1265-1276.
    >> Share

    July 2021
  29. GARNIER-CRUSSARD A, Bougacha S, Wirth M, Dautricourt S, et al
    White matter hyperintensity topography in Alzheimer's disease and links to cognition.
    Alzheimers Dement. 2021 Jul 28. doi: 10.1002/alz.12410.
    >> Share

  30. BOADA M, Rodrigo A, Jessen F, Wimblad B, et al
    Complementary pre-screening strategies to uncover hidden prodromal and mild Alzheimer's disease: Results from the MOPEAD project.
    Alzheimers Dement. 2021 Jul 26. doi: 10.1002/alz.12441.
    >> Share

  31. HOSCHEIDT S, Sanderlin AH, Baker LD, Jung Y, et al
    Mediterranean and Western diet effects on Alzheimer's disease biomarkers, cerebral perfusion, and cognition in mid-life: A randomized trial.
    Alzheimers Dement. 2021 Jul 26. doi: 10.1002/alz.12421.
    >> Share

  32. VAN HARTEN AC, Wiste HJ, Weigand SD, Mielke MM, et al
    Detection of Alzheimer's disease amyloid beta 1-42, p-tau, and t-tau assays.
    Alzheimers Dement. 2021 Jul 26. doi: 10.1002/alz.12406.
    >> Share

  33. KULMINSKI AM, Philipp I, Loika Y, He L, et al
    Protective association of the epsilon2/epsilon3 heterozygote with Alzheimer's disease is strengthened by TOMM40-APOE variants in men.
    Alzheimers Dement. 2021 Jul 26. doi: 10.1002/alz.12413.
    >> Share

  34. BOCHE D, Gordon MN
    Diversity of transcriptomic microglial phenotypes in aging and Alzheimer's disease.
    Alzheimers Dement. 2021 Jul 5. doi: 10.1002/alz.12389.
    >> Share

  35. BAO H, Liu Y, Zhang M, Chen Z, et al
    Increased beta-site APP cleaving enzyme 1-mediated insulin receptor cleavage in type 2 diabetes mellitus with cognitive impairment.
    Alzheimers Dement. 2021;17:1097-1108.
    >> Share

    June 2021
  36. ZHANG X, Farrell JJ, Tong T, Hu J, et al
    Association of mitochondrial variants and haplogroups identified by whole exome sequencing with Alzheimer's disease.
    Alzheimers Dement. 2021 Jun 20. doi: 10.1002/alz.12396.
    >> Share

  37. TEERLINK CC, Miller JB, Vance EL, Staley LA, et al
    Analysis of high-risk pedigrees identifies 12 candidate variants for Alzheimer's disease.
    Alzheimers Dement. 2021 Jun 20. doi: 10.1002/alz.12397.
    >> Share

  38. ZHONG W, Wu A, Berglund K, Gu X, et al
    Pathogenesis of sporadic Alzheimer's disease by deficiency of NMDA receptor subunit GluN3A.
    Alzheimers Dement. 2021 Jun 20. doi: 10.1002/alz.12398.
    >> Share

  39. JANELIDZE S, Palmqvist S, Leuzy A, Stomrud E, et al
    Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Abeta42/Abeta40 and p-tau.
    Alzheimers Dement. 2021 Jun 20. doi: 10.1002/alz.12395.
    >> Share

  40. BIRKENBIHL C, Salimi Y, Frohlich H
    Unraveling the heterogeneity in Alzheimer's disease progression across multiple cohorts and the implications for data-driven disease modeling.
    Alzheimers Dement. 2021 Jun 9. doi: 10.1002/alz.12387.
    >> Share

  41. LOPEZ-RODRIGUEZ AB, Hennessy E, Murray CL, Nazmi A, et al
    Acute systemic inflammation exacerbates neuroinflammation in Alzheimer's disease: IL-1beta drives amplified responses in primed astrocytes and neuronal network dysfunction.
    Alzheimers Dement. 2021 Jun 3. doi: 10.1002/alz.12341.
    >> Share

  42. TEMP AGM, Lutz MW, Trepel D, Tang Y, et al
    How Bayesian statistics may help answer some of the controversial questions in clinical research on Alzheimer's disease.
    Alzheimers Dement. 2021;17:917-919.
    >> Share

  43. FRANZMEIER N, Ossenkoppele R, Brendel M, Rubinski A, et al
    The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster Abeta-associated tau accumulation and cognitive decline.
    Alzheimers Dement. 2021 Jun 1. doi: 10.1002/alz.12371.
    >> Share

  44. RICHARD E, den Brok MGHE, van Gool WA
    Bayes analysis supports null hypothesis of anti-amyloid beta therapy in Alzheimer's disease.
    Alzheimers Dement. 2021;17:1051-1055.
    >> Share

  45. DE ERAUSQUIN GA, Snyder H, Carrillo M, Hosseini AA, et al
    The chronic neuropsychiatric sequelae of COVID-19: The need for a prospective study of viral impact on brain functioning.
    Alzheimers Dement. 2021;17:1056-1065.
    >> Share

    May 2021
  46. SEXTON CE, Anstey KJ, Baldacci F, Barnum CJ, et al
    Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney.
    Alzheimers Dement. 2021 May 31. doi: 10.1002/alz.12380.
    >> Share

  47. O'BRYANT SE, Zhang F, Petersen M, Hall JR, et al
    A blood screening tool for detecting mild cognitive impairment and Alzheimer's disease among community-dwelling Mexican Americans and non-Hispanic Whites: A method for increasing representation of diverse populations in clinical research.
    Alzheimers Dement. 2021 May 31. doi: 10.1002/alz.12382.
    >> Share

    Beta-amyloid pore linked to controlled calcium influx into the cell: A new paradigm for Alzheimer's Disease.
    Alzheimers Dement. 2021 May 29. doi: 10.1002/alz.12373.
    >> Share

  49. SCHWAHN C, Frenzel S, Holtfreter B, Van der Auwera S, et al
    Effect of periodontal treatment on preclinical Alzheimer's disease-Results of a trial emulation approach.
    Alzheimers Dement. 2021 May 29. doi: 10.1002/alz.12378.
    >> Share

  50. RAJAN KB, Weuve J, Barnes LL, McAninch EA, et al
    Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020-2060).
    Alzheimers Dement. 2021 May 27. doi: 10.1002/alz.12362.
    >> Share

  51. HAMPEL H, Shaw LM, Aisen P, Chen C, et al
    State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease.
    Alzheimers Dement. 2021 May 27. doi: 10.1002/alz.12372.
    >> Share

  52. JIANG Y, Zhou X, Ip FC, Chan P, et al
    Large-scale plasma proteomic profiling identifies a high-performance biomarker panel for Alzheimer's disease screening and staging.
    Alzheimers Dement. 2021 May 25. doi: 10.1002/alz.12369.
    >> Share

  53. APOSTOLOVA LG, Aisen P, Eloyan A, Fagan A, et al
    The Longitudinal Early-onset Alzheimer's Disease Study (LEADS): Framework and methodology.
    Alzheimers Dement. 2021 May 21. doi: 10.1002/alz.12350.
    >> Share

  54. STERN Y, Stallard E, Kinosian B, Zhu C, et al
    Validation and demonstration of a new comprehensive model of Alzheimer's disease progression.
    Alzheimers Dement. 2021 May 14. doi: 10.1002/alz.12336.
    >> Share

  55. HONG S, Dobricic V, Ohlei O, Bos I, et al
    TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels.
    Alzheimers Dement. 2021 May 14. doi: 10.1002/alz.12330.
    >> Share

  56. LIBIGER O, Shaw LM, Watson MH, Nairn AC, et al
    Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease.
    Alzheimers Dement. 2021 May 13. doi: 10.1002/alz.12353.
    >> Share

  57. GUSTAVSSON A, Raket LL, Lilja M, Rutten-Jacobs L, et al
    Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new disease-modifying treatments-EQ-5D data from the Swedish BioFINDER study.
    Alzheimers Dement. 2021 May 13. doi: 10.1002/alz.12355.
    >> Share

  58. MORGAN DG, Mielke MM
    Knowledge gaps in Alzheimer's disease immune biomarker research.
    Alzheimers Dement. 2021 May 13. doi: 10.1002/alz.12342.
    >> Share

  59. OSSENKOPPELE R, Hansson O
    Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease.
    Alzheimers Dement. 2021 May 13. doi: 10.1002/alz.12356.
    >> Share

  60. MADRASI K, Das R, Mohmmadabdul H, Lin L, et al
    Systematic in silico analysis of clinically tested drugs for reducing amyloid-beta plaque accumulation in Alzheimer's disease.
    Alzheimers Dement. 2021 May 2. doi: 10.1002/alz.12312.
    >> Share

  61. Association commits $14 million to novel drug trials in rare form of Alzheimer's.
    Alzheimers Dement. 2021;17:910.
    >> Share

  62. STANLEY J, Howlett SE, Dunn T, Rockwood K, et al
    The Clinician's Interview-Based Impression of Change (Plus caregiver input) and goal attainment in two dementia drug trials: Clinical meaningfulness and the initial treatment response.
    Alzheimers Dement. 2021;17:856-865.
    >> Share

  63. MIELKE MM, Przybelski SA, Lesnick TG, Kern S, et al
    Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers.
    Alzheimers Dement. 2021;17:801-812.
    >> Share

  64. WOODWORTH DC, Nguyen HL, Khan Z, Kawas CH, et al
    Utility of MRI in the identification of hippocampal sclerosis of aging.
    Alzheimers Dement. 2021;17:847-855.
    >> Share

  65. COUSINS KAQ, Phillips JS, Irwin DJ, Lee EB, et al
    ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration.
    Alzheimers Dement. 2021;17:822-830.
    >> Share

    April 2021
  66. RANASINGHE KG, Petersen C, Kudo K, Mizuiri D, et al
    Reduced synchrony in alpha oscillations during life predicts post mortem neurofibrillary tangle density in early-onset and atypical Alzheimer's disease.
    Alzheimers Dement. 2021 Apr 21. doi: 10.1002/alz.12349.
    >> Share

  67. LI X, Tsolis KC, Koper MJ, Ronisz A, et al
    Sequence of proteome profiles in preclinical and symptomatic Alzheimer's disease.
    Alzheimers Dement. 2021 Apr 19. doi: 10.1002/alz.12345.
    >> Share

  68. BABILONI C, Arakaki X, Azami H, Bennys K, et al
    Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel.
    Alzheimers Dement. 2021 Apr 15. doi: 10.1002/alz.12311.
    >> Share

  69. MOELLER S, Sridhar J, Martersteck A, Coventry C, et al
    Functional decline in the aphasic variant of Alzheimer's disease.
    Alzheimers Dement. 2021 Apr 8. doi: 10.1002/alz.12331.
    >> Share

  70. MOLONEY CM, Lowe VJ, Murray ME
    Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research.
    Alzheimers Dement. 2021 Apr 2. doi: 10.1002/alz.12321.
    >> Share

  71. PROKOPENKO D, Morgan SL, Mullin K, Hofmann O, et al
    Whole-genome sequencing reveals new Alzheimer's disease-associated rare variants in loci related to synaptic function and neuronal development.
    Alzheimers Dement. 2021 Apr 2. doi: 10.1002/alz.12319.
    >> Share

  72. SABBAGH MN, Cummings J
    Open Peer Commentary to "Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019".
    Alzheimers Dement. 2021;17:702-703.
    >> Share

  73. KULLER LH, Lopez OL
    ENGAGE and EMERGE: Truth and consequences?
    Alzheimers Dement. 2021;17:692-695.
    >> Share

  74. BRAY MJC, Richey LN, Bryant BR, Krieg A, et al
    Traumatic brain injury alters neuropsychiatric symptomatology in all-cause dementia.
    Alzheimers Dement. 2021;17:686-691.
    >> Share

  75. PLANCHE V, Bouteloup V, Mangin JF, Dubois B, et al
    Clinical relevance of brain atrophy subtypes categorization in memory clinics.
    Alzheimers Dement. 2021;17:641-652.
    >> Share

  76. STAFFARONI AM, Asken BM, Casaletto KB, Fonseca C, et al
    Development and validation of the Uniform Data Set (v3.0) executive function composite score (UDS3-EF).
    Alzheimers Dement. 2021;17:574-583.
    >> Share

  77. KNOPMAN DS, Jones DT, Greicius MD
    Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019.
    Alzheimers Dement. 2021;17:696-701.
    >> Share

    March 2021
  78. CHONG JR, Ashton NJ, Karikari TK, Tanaka T, et al
    Plasma P-tau181 to Abeta42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease.
    Alzheimers Dement. 2021 Mar 31. doi: 10.1002/alz.12332.
    >> Share

  79. SHI L, Winchester LM, Westwood S, Baird AL, et al
    Replication study of plasma proteins relating to Alzheimer's pathology.
    Alzheimers Dement. 2021 Mar 31. doi: 10.1002/alz.12322.
    >> Share

  80. HANSSON O, Batrla R, Brix B, Carrillo MC, et al
    The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid beta and tau.
    Alzheimers Dement. 2021 Mar 31. doi: 10.1002/alz.12316.
    >> Share

  81. Register for May AAIC(R) Satellite Symposium and second Latinos & Alzheimer's symposium.
    Alzheimers Dement. 2021 Mar 31. doi: 10.1002/alz.12337.
    >> Share

  82. AKHTER-KHAN SC, Tao Q, Ang TFA, Itchapurapu IS, et al
    Associations of loneliness with risk of Alzheimer's disease dementia in the Framingham Heart Study.
    Alzheimers Dement. 2021 Mar 24. doi: 10.1002/alz.12327.
    >> Share

  83. 2021 Alzheimer's disease facts and figures.
    Alzheimers Dement. 2021 Mar 23. doi: 10.1002/alz.12328.
    >> Share

  84. BECKMAN D, Chakrabarty P, Ott S, Dao A, et al
    A novel tau-based rhesus monkey model of Alzheimer's pathogenesis.
    Alzheimers Dement. 2021 Mar 18. doi: 10.1002/alz.12318.
    >> Share

  85. KOCIOLEK AJ, Fernandez KK, Jin Z, Cosentino S, et al
    Extrapyramidal signs and Alzheimer's disease prognosis in a multiethnic, community-based sample of demented elders.
    Alzheimers Dement. 2021 Mar 12. doi: 10.1002/alz.12309.
    >> Share

  86. DISBROW E, Stokes KY, Ledbetter C, Patterson J, et al
    Plasma hydrogen sulfide: A biomarker of Alzheimer's disease and related dementias.
    Alzheimers Dement. 2021 Mar 12. doi: 10.1002/alz.12305.
    >> Share

  87. FALGAS N, Walsh CM, Neylan TC, Grinberg LT, et al
    Deepen into sleep and wake patterns across Alzheimer's disease phenotypes.
    Alzheimers Dement. 2021 Mar 12. doi: 10.1002/alz.12304.
    >> Share

  88. RAHMAN M, White EM, Mills C, Thomas KS, et al
    Rural-urban differences in diagnostic incidence and prevalence of Alzheimer's disease and related dementias.
    Alzheimers Dement. 2021 Mar 4. doi: 10.1002/alz.12285.
    >> Share

  89. SALVADO G, Mila-Aloma M, Shekari M, Minguillon C, et al
    Cerebral amyloid-beta load is associated with neurodegeneration and gliosis: Mediation by p-tau and interactions with risk factors early in the Alzheimer's continuum.
    Alzheimers Dement. 2021 Mar 4. doi: 10.1002/alz.12245.
    >> Share

  90. TURNER DA, Degan S, Hoffmann U, Galeffi F, et al
    CVN-AD Alzheimer's mice show premature reduction in neurovascular coupling in response to spreading depression and anoxia compared to aged controls.
    Alzheimers Dement. 2021 Mar 3. doi: 10.1002/alz.12289.
    >> Share

  91. MASEREJIAN N, Krzywy H, Eaton S, Galvin JE, et al
    Cognitive measures lacking in EHR prior to dementia or Alzheimer's disease diagnosis.
    Alzheimers Dement. 2021 Mar 3. doi: 10.1002/alz.12280.
    >> Share

  92. SAITO ER, Miller JB, Harari O, Cruchaga C, et al
    Alzheimer's disease alters oligodendrocytic glycolytic and ketolytic gene expression.
    Alzheimers Dement. 2021 Mar 2. doi: 10.1002/alz.12310.
    >> Share

  93. LI Y, Xiong C, Aschenbrenner AJ, Chang CH, et al
    Item response theory analysis of the Clinical Dementia Rating.
    Alzheimers Dement. 2021;17:534-542.
    >> Share

  94. FANI L, Ahmad S, Ikram MK, Ghanbari M, et al
    Immunity and amyloid beta, total tau and neurofilament light chain: Findings from a community-based cohort study.
    Alzheimers Dement. 2021;17:446-456.
    >> Share

  95. GRANOT-HERSHKOVITZ E, Tarraf W, Kurniansyah N, Daviglus M, et al
    APOE alleles' association with cognitive function differs across Hispanic/Latino groups and genetic ancestry in the study of Latinos-investigation of neurocognitive aging (HCHS/SOL).
    Alzheimers Dement. 2021;17:466-474.
    >> Share

    February 2021
  96. ASHFORD MT, Veitch DP, Neuhaus J, Nosheny RL, et al
    The search for a convenient procedure to detect one of the earliest signs of Alzheimer's disease: A systematic review of the prediction of brain amyloid status.
    Alzheimers Dement. 2021 Feb 13. doi: 10.1002/alz.12253.
    >> Share

  97. BRICKMAN AM, Manly JJ, Honig LS, Sanchez D, et al
    Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study.
    Alzheimers Dement. 2021 Feb 13. doi: 10.1002/alz.12301.
    >> Share

  98. IZZO NJ, Yuede CM, LaBarbera KM, Limegrover CS, et al
    Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.
    Alzheimers Dement. 2021 Feb 8. doi: 10.1002/alz.12302.
    >> Share

  99. BLEILE L
    Alzheimer's Association Update.
    Alzheimers Dement. 2021 Feb 4. doi: 10.1002/alz.12306.
    >> Share

  100. WANG R, Qiu C, Dintica CS, Shang Y, et al
    Shared risk and protective factors between Alzheimer's disease and ischemic stroke: A population-based longitudinal study.
    Alzheimers Dement. 2021 Feb 1. doi: 10.1002/alz.12203.
    >> Share

  101. GUZMAN-VELEZ E, Zetterberg H, Fox-Fuller JT, Vila-Castelar C, et al
    Associations between plasma neurofilament light, in vivo brain pathology, and cognition in non-demented individuals with autosomal-dominant Alzheimer's disease.
    Alzheimers Dement. 2021 Feb 1. doi: 10.1002/alz.12248.
    >> Share

  102. GRISWOLD AJ, Celis K, Bussies PL, Rajabli F, et al
    Increased APOE epsilon4 expression is associated with the difference in Alzheimer's disease risk from diverse ancestral backgrounds.
    Alzheimers Dement. 2021 Feb 1. doi: 10.1002/alz.12287.
    >> Share

  103. HAGHANI A, Thorwald M, Morgan TE, Finch CE, et al
    The APOE gene cluster responds to air pollution factors in mice with coordinated expression of genes that differs by age in humans.
    Alzheimers Dement. 2021;17:175-190.
    >> Share

  104. CHEN XQ, Salehi A, Pearn ML, Overk C, et al
    Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model.
    Alzheimers Dement. 2021;17:271-292.
    >> Share

  105. BLUE EE, Thornton TA, Kooperberg C, Liu S, et al
    Non-coding variants in MYH11, FZD3, and SORCS3 are associated with dementia in women.
    Alzheimers Dement. 2021;17:215-225.
    >> Share

  106. DE LEEUW FA, Karamujic-Comic H, Tijms BM, Peeters CFW, et al
    Circulating metabolites are associated with brain atrophy and white matter hyperintensities.
    Alzheimers Dement. 2021;17:205-214.
    >> Share

    January 2021
  107. AYTON S, Portbury S, Kalinowski P, Agarwal P, et al
    Regional brain iron associated with deterioration in Alzheimer's disease: A large cohort study and theoretical significance.
    Alzheimers Dement. 2021 Jan 25. doi: 10.1002/alz.12282.
    >> Share

  108. SIMREN J, Leuzy A, Karikari TK, Hye A, et al
    The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease.
    Alzheimers Dement. 2021 Jan 25. doi: 10.1002/alz.12283.
    >> Share

  109. GERMANN J, Elias GJB, Boutet A, Narang K, et al
    Brain structures and networks responsible for stimulation-induced memory flashbacks during forniceal deep brain stimulation for Alzheimer's disease.
    Alzheimers Dement. 2021 Jan 21. doi: 10.1002/alz.12238.
    >> Share

  110. BRYAN J, Mandan A, Kamat G, Gottschalk WK, et al
    Likelihood ratio statistics for gene set enrichment in Alzheimer's disease pathways.
    Alzheimers Dement. 2021 Jan 21. doi: 10.1002/alz.12223.
    >> Share

  111. LUCKETT PH, McCullough A, Gordon BA, Strain J, et al
    Modeling autosomal dominant Alzheimer's disease with machine learning.
    Alzheimers Dement. 2021 Jan 21. doi: 10.1002/alz.12259.
    >> Share

  112. LI HD, Funk CC, McFarland K, Dammer EB, et al
    Integrative functional genomic analysis of intron retention in human and mouse brain with Alzheimer's disease.
    Alzheimers Dement. 2021 Jan 21. doi: 10.1002/alz.12254.
    >> Share

  113. Alzheimer's Association International Conference Neuroscience Next focused on early career researchers across all of neuroscience.
    Alzheimers Dement. 2021;17:138-139.
    >> Share

  114. CHIARI A, Vinceti G, Adani G, Tondelli M, et al
    Epidemiology of early onset dementia and its clinical presentations in the province of Modena, Italy.
    Alzheimers Dement. 2021;17:81-88.
    >> Share

    December 2020
  115. VAN HULLE C, Jonaitis EM, Betthauser TJ, Batrla R, et al
    An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum.
    Alzheimers Dement. 2020 Dec 18. doi: 10.1002/alz.12204.
    >> Share

  116. LYSSENKO NN, Pratico D
    ABCA7 and the altered lipidostasis hypothesis of Alzheimer's disease.
    Alzheimers Dement. 2020 Dec 17. doi: 10.1002/alz.12220.
    >> Share

    Recognizing African-American contributions to neurology: The role of Solomon Carter Fuller (1872-1953) in Alzheimer's disease research.
    Alzheimers Dement. 2020 Dec 15. doi: 10.1002/alz.12183.
    >> Share

  118. AUDRAIN M, Haure-Mirande JV, Mleczko J, Wang M, et al
    Reactive or transgenic increase in microglial TYROBP reveals a TREM2-independent TYROBP-APOE link in wild-type and Alzheimer's-related mice.
    Alzheimers Dement. 2020 Dec 12. doi: 10.1002/alz.12256.
    >> Share

  119. KIM YW, Al-Ramahi I, Koire A, Wilson SJ, et al
    Harnessing the paradoxical phenotypes of APOE varepsilon2 and APOE varepsilon4 to identify genetic modifiers in Alzheimer's disease.
    Alzheimers Dement. 2020 Dec 7. doi: 10.1002/alz.12240.
    >> Share

  120. FRYE BM, Craft S, Register TC, Andrews RN, et al
    Diet, psychosocial stress, and Alzheimer's disease-related neuroanatomy in female nonhuman primates.
    Alzheimers Dement. 2020 Dec 3. doi: 10.1002/alz.12232.
    >> Share

    November 2020
  121. KARIKARI TK, Emersic A, Vrillon A, Lantero-Rodriguez J, et al
    Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis.
    Alzheimers Dement. 2020 Nov 30. doi: 10.1002/alz.12236.
    >> Share

  122. LLIBRE-GUERRA JJ, Li Y, Allegri RF, Mendez PC, et al
    Dominantly inherited Alzheimer's disease in Latin America: Genetic heterogeneity and clinical phenotypes.
    Alzheimers Dement. 2020 Nov 23. doi: 10.1002/alz.12227.
    >> Share

  123. DUENAS MR, Snyder PJ
    Alzheimer's team care approach-akin to diabetes-in the development, validation, and population assessment of retinal biomarkers for disease.
    Alzheimers Dement. 2020 Nov 23. doi: 10.1002/alz.12234.
    >> Share

  124. SPENCER BE, Digma LA, Jennings RG, Brewer JB, et al
    Gene- and age-informed screening for preclinical Alzheimer's disease trials.
    Alzheimers Dement. 2020 Nov 23. doi: 10.1002/alz.12207.
    >> Share

  125. HITHERSAY R, Baksh RA, Startin CM, Wijeratne P, et al
    Optimal age and outcome measures for Alzheimer's disease prevention trials in people with Down syndrome.
    Alzheimers Dement. 2020 Nov 23. doi: 10.1002/alz.12222.
    >> Share

  126. PENTZ R, Iulita MF, Ducatenzeiler A, Videla L, et al
    Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study.
    Alzheimers Dement. 2020 Nov 23. doi: 10.1002/alz.12229.
    >> Share

  127. MONTAL V, Vilaplana E, Pegueroles J, Bejanin A, et al
    Biphasic cortical macro- and microstructural changes in autosomal dominant Alzheimer's disease.
    Alzheimers Dement. 2020 Nov 16. doi: 10.1002/alz.12224.
    >> Share

  128. JESSEN F, Kleineidam L, Wolfsgruber S, Bickel H, et al
    Prediction of dementia of Alzheimer type by different types of subjective cognitive decline.
    Alzheimers Dement. 2020 Nov 2. doi: 10.1002/alz.12163.
    >> Share

  129. Alzheimer's Association pays tribute to former Chief Science Officer William (Bill) Thies, PhD.
    Alzheimers Dement. 2020;16:1600-1605.
    >> Share

    October 2020
  130. SOHEILI-NEZHAD S, van der Linden RJ, Olde Rikkert M, Sprooten E, et al
    Long genes are more frequently affected by somatic mutations and show reduced expression in Alzheimer's disease: Implications for disease etiology.
    Alzheimers Dement. 2020 Oct 19. doi: 10.1002/alz.12211.
    >> Share

  131. ARNSTEN AFT, Datta D, Tredici KD, Braak H, et al
    Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer's disease.
    Alzheimers Dement. 2020 Oct 19. doi: 10.1002/alz.12192.
    >> Share

  132. WESSELS AM, Lines C, Stern RA, Kost J, et al
    Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease.
    Alzheimers Dement. 2020 Oct 13. doi: 10.1002/alz.12164.
    >> Share

  133. MECCA AP, van Dyck CH
    Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
    Alzheimers Dement. 2020 Oct 12. doi: 10.1002/alz.12190.
    >> Share

  134. SNYDER PJ, Alber J, Alt C, Bain LJ, et al
    Retinal imaging in Alzheimer's and neurodegenerative diseases.
    Alzheimers Dement. 2020 Oct 8. doi: 10.1002/alz.12179.
    >> Share

  135. THUNELL J, Chen Y, Joyce G, Barthold D, et al
    Drug therapies for chronic conditions and risk of Alzheimer's disease and related dementias: A scoping review.
    Alzheimers Dement. 2020 Oct 8. doi: 10.1002/alz.12175.
    >> Share

  136. JAIN S, Rosenbaum PR, Reiter JG, Hoffman G, et al
    Using Medicare claims in identifying Alzheimer's disease and related dementias.
    Alzheimers Dement. 2020 Oct 8. doi: 10.1002/alz.12199.
    >> Share

  137. HOU X, Watzlawik JO, Cook C, Liu CC, et al
    Mitophagy alterations in Alzheimer's disease are associated with granulovacuolar degeneration and early tau pathology.
    Alzheimers Dement. 2020 Oct 8. doi: 10.1002/alz.12198.
    >> Share

  138. BUBU OM, Umasabor-Bubu OQ, Turner AD, Parekh A, et al
    Self-reported obstructive sleep apnea, amyloid and tau burden, and Alzheimer's disease time-dependent progression.
    Alzheimers Dement. 2020 Oct 8. doi: 10.1002/alz.12184.
    >> Share

    September 2020
  139. FRANCESCO DL, Koch G
    Synaptic impairment: The new battlefield of Alzheimer's disease.
    Alzheimers Dement. 2020 Sep 18. doi: 10.1002/alz.12189.
    >> Share

  140. 36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease.
    Alzheimers Dement. 2020 Sep 13. doi: 10.1002/alz.12172.
    >> Share

  141. JIA L, Xu H, Chen S, Wang X, et al
    The APOE epsilon4 exerts differential effects on familial and other subtypes of Alzheimer's disease.
    Alzheimers Dement. 2020 Sep 3. doi: 10.1002/alz.12153.
    >> Share

  142. DE LEON J, Grasso SM, Welch A, Miller Z, et al
    Effects of bilingualism on age at onset in two clinical Alzheimer's disease variants.
    Alzheimers Dement. 2020 Sep 3. doi: 10.1002/alz.12170.
    >> Share

    August 2020
  143. LIU CC, Yamazaki Y, Heckman MG, Martens YA, et al
    Tau and apolipoprotein E modulate cerebrovascular tight junction integrity independent of cerebral amyloid angiopathy in Alzheimer's disease.
    Alzheimers Dement. 2020 Aug 22. doi: 10.1002/alz.12104.
    >> Share

  144. FRISONI GB, Molinuevo JL, Altomare D, Carrera E, et al
    Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies.
    Alzheimers Dement. 2020 Aug 20. doi: 10.1002/alz.12132.
    >> Share

  145. FINSTERWALDER S, Vlegels N, Gesierich B, Araque Caballero MA, et al
    Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients.
    Alzheimers Dement. 2020 Aug 18. doi: 10.1002/alz.12150.
    >> Share

  146. LIN PJ, Cohen JT, Neumann PJ
    Preparing the health-care system to pay for new Alzheimer's drugs.
    Alzheimers Dement. 2020 Aug 18. doi: 10.1002/alz.12155.
    >> Share

  147. DENNY A, Streitz M, Stock K, Balls-Berry JE, et al
    Perspective on the "African American participation in Alzheimer disease research: Effective strategies" workshop, 2018.
    Alzheimers Dement. 2020 Aug 17. doi: 10.1002/alz.12160.
    >> Share

  148. WU CY, Ouk M, Wong YY, Anita NZ, et al
    Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status.
    Alzheimers Dement. 2020 Aug 16. doi: 10.1002/alz.12161.
    >> Share

  149. MOK VCT, Pendlebury S, Wong A, Alladi S, et al
    Tackling challenges in care of Alzheimer's disease and other dementias amid the COVID-19 pandemic, now and in the future.
    Alzheimers Dement. 2020 Aug 12. doi: 10.1002/alz.12143.
    >> Share

  150. JIA L, Zhu M, Kong C, Pang Y, et al
    Blood neuro-exosomal synaptic proteins predict Alzheimer's disease at the asymptomatic stage.
    Alzheimers Dement. 2020 Aug 10. doi: 10.1002/alz.12166.
    >> Share

  151. NHO K, Nudelman K, Allen M, Hodges A, et al
    Genome-wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology.
    Alzheimers Dement. 2020 Aug 5. doi: 10.1002/alz.12092.
    >> Share

    July 2020
  152. GUSTAFSON DR, Backman K, Scarmeas N, Stern Y, et al
    Dietary fatty acids and risk of Alzheimer's disease and related dementias: Observations from the Washington Heights-Hamilton Heights-Inwood Columbia Aging Project (WHICAP).
    Alzheimers Dement. 2020 Jul 27. doi: 10.1002/alz.12154.
    >> Share

  153. BOADA M, Lopez OL, Olazaran J, Nunez L, et al
    A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study.
    Alzheimers Dement. 2020 Jul 27. doi: 10.1002/alz.12137.
    >> Share

  154. VIDONI ED, Choi IY, Lee P, Reed G, et al
    Safety and target engagement profile of two oxaloacetate doses in Alzheimer's patients.
    Alzheimers Dement. 2020 Jul 27. doi: 10.1002/alz.12156.
    >> Share

  155. KLING MA, Goodenowe DB, Senanayake V, MahmoudianDehkordi S, et al
    Circulating ethanolamine plasmalogen indices in Alzheimer's disease: Relation to diagnosis, cognition, and CSF tau.
    Alzheimers Dement. 2020 Jul 27. doi: 10.1002/alz.12110.
    >> Share

  156. XU W, Tan L, Su BJ, Yu H, et al
    Sleep characteristics and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact older adults: The CABLE study.
    Alzheimers Dement. 2020 Jul 13. doi: 10.1002/alz.12117.
    >> Share

    June 2020
  157. CASELLI RJ, Knopman DS, Bu G
    An agnostic reevaluation of the amyloid cascade hypothesis of Alzheimer's disease pathogenesis: The role of APP homeostasis.
    Alzheimers Dement. 2020 Jun 26. doi: 10.1002/alz.12124.
    >> Share

  158. LUTZ MW, Luo S, Williamson DE, Chiba-Falek O, et al
    Shared genetic etiology underlying late-onset Alzheimer's disease and posttraumatic stress syndrome.
    Alzheimers Dement. 2020 Jun 26. doi: 10.1002/alz.12128.
    >> Share

  159. EREN E, Hunt JFV, Shardell M, Chawla S, et al
    Extracellular vesicle biomarkers of Alzheimer's disease associated with sub-clinical cognitive decline in late middle age.
    Alzheimers Dement. 2020 Jun 26. doi: 10.1002/alz.12130.
    >> Share

  160. New Thinking About Thinking, Part 3. Advice on preparing a successful manuscript for Alzheimer's & Dementia.
    Alzheimers Dement. 2020 Jun 24. doi: 10.1002/alz.12141.
    >> Share

  161. MILA-ALOMA M, Salvado G, Gispert JD, Vilor-Tejedor N, et al
    Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum.
    Alzheimers Dement. 2020 Jun 23. doi: 10.1002/alz.12131.
    >> Share

  162. SHERVA R, Gross A, Mukherjee S, Koesterer R, et al
    Genome-wide association study of rate of cognitive decline in Alzheimer's disease patients identifies novel genes and pathways.
    Alzheimers Dement. 2020 Jun 23. doi: 10.1002/alz.12106.
    >> Share

  163. AZAR M, Chapman S, Gu Y, Leverenz JB, et al
    Cognitive tests aid in clinical differentiation of Alzheimer's disease versus Alzheimer's disease with Lewy body disease: Evidence from a pathological study.
    Alzheimers Dement. 2020 Jun 19. doi: 10.1002/alz.12120.
    >> Share

  164. SNYDER HM, Bain LJ, Brickman AM, Carrillo MC, et al
    Further understanding the connection between Alzheimer's disease and Down syndrome.
    Alzheimers Dement. 2020 Jun 16. doi: 10.1002/alz.12112.
    >> Share

  165. SWERDLOW RH, Hui D, Chalise P, Sharma P, et al
    Exploratory analysis of mtDNA haplogroups in two Alzheimer's longitudinal cohorts.
    Alzheimers Dement. 2020 Jun 16. doi: 10.1002/alz.12119.
    >> Share

  166. COCROFT S, Welsh-Bohmer KA, Plassman BL, Chanti-Ketterl M, et al
    Racially diverse participant registries to facilitate the recruitment of African Americans into presymptomatic Alzheimer's disease studies.
    Alzheimers Dement. 2020 Jun 16. doi: 10.1002/alz.12048.
    >> Share

  167. BERMEJO-PAREJA F, Del Ser T, Valenti M, de la Fuente M, et al
    Salivary lactoferrin as biomarker for Alzheimer's disease: Brain-immunity interactions.
    Alzheimers Dement. 2020 Jun 16. doi: 10.1002/alz.12107.
    >> Share

  168. BI D, Wen L, Wu Z, Shen Y, et al
    GABAergic dysfunction in excitatory and inhibitory (E/I) imbalance drives the pathogenesis of Alzheimer's disease.
    Alzheimers Dement. 2020 Jun 16. doi: 10.1002/alz.12088.
    >> Share

  169. GENTREAU M, Chuy V, Feart C, Samieri C, et al
    Refined carbohydrate-rich diet is associated with long-term risk of dementia and Alzheimer's disease in apolipoprotein E epsilon4 allele carriers.
    Alzheimers Dement. 2020 Jun 7. doi: 10.1002/alz.12114.
    >> Share

  170. FIRTH NC, Primativo S, Brotherhood E, Young AL, et al
    Sequences of cognitive decline in typical Alzheimer's disease and posterior cortical atrophy estimated using a novel event-based model of disease progression.
    Alzheimers Dement. 2020 Jun 2. doi: 10.1002/alz.12083.
    >> Share

    May 2020
  171. ORDING AG, Horvath-Puho E, Veres K, Glymour MM, et al
    Cancer and risk of Alzheimer's disease: Small association in a nationwide cohort study.
    Alzheimers Dement. 2020 May 20. doi: 10.1002/alz.12090.
    >> Share

  172. KNOPMAN D, Lemere CA, Lamb BT, Craft S, et al
    Scientific Advising and Reviewing: On strengthening the bond between the Alzheimer's Association and the scientific community.
    Alzheimers Dement. 2020 May 19. doi: 10.1002/alz.12059.
    >> Share

  173. RIOS-ROMENETS S, Lopera F, Sink KM, Hu N, et al
    Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia Trial.
    Alzheimers Dement. 2020 May 17. doi: 10.1002/alz.12109.
    >> Share

  174. MECCA AP, Chen MK, O'Dell RS, Naganawa M, et al
    In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET.
    Alzheimers Dement. 2020 May 13. doi: 10.1002/alz.12097.
    >> Share

  175. MOORE EE, Gifford KA, Khan OA, Liu D, et al
    Cerebrospinal fluid biomarkers of neurodegeneration, synaptic dysfunction, and axonal injury relate to atrophy in structural brain regions specific to Alzheimer's disease.
    Alzheimers Dement. 2020 May 6. doi: 10.1002/alz.12087.
    >> Share

  176. RENTZ DM, Wessels AM, Bain LJ, Weber CJ, et al
    Clinical meaningfulness addressed at Alzheimer's Association Research Roundtable.
    Alzheimers Dement. 2020;16:814.
    >> Share

    April 2020
  177. JORGENSEN IF, Aguayo-Orozco A, Lademann M, Brunak S, et al
    Age-stratified longitudinal study of Alzheimer's and vascular dementia patients.
    Alzheimers Dement. 2020 Apr 27. doi: 10.1002/alz.12091.
    >> Share

  178. DE FLORES R, Wisse LEM, Das SR, Xie L, et al
    Contribution of mixed pathology to medial temporal lobe atrophy in Alzheimer's disease.
    Alzheimers Dement. 2020 Apr 22. doi: 10.1002/alz.12079.
    >> Share

  179. MURAOKA S, DeLeo AM, Sethi MK, Yukawa-Takamatsu K, et al
    Proteomic and biological profiling of extracellular vesicles from Alzheimer's disease human brain tissues.
    Alzheimers Dement. 2020 Apr 17. doi: 10.1002/alz.12089.
    >> Share

  180. TRARES K, Gao X, Perna L, Rujescu D, et al
    Associations of urinary 8-iso-prostaglandin F2alpha levels with all-cause dementia, Alzheimer's disease, and vascular dementia incidence: results from a prospective cohort study.
    Alzheimers Dement. 2020 Apr 12. doi: 10.1002/alz.12081.
    >> Share

  181. LOPES ALVES I, Collij LE, Altomare D, Frisoni GB, et al
    Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study.
    Alzheimers Dement. 2020 Apr 12. doi: 10.1002/alz.12069.
    >> Share

  182. DONOHUE MC, Model F, Delmar P, Volye N, et al
    Initiation of symptomatic medication in Alzheimer's disease clinical trials: Hypothetical versus treatment policy approach.
    Alzheimers Dement. 2020 Apr 8. doi: 10.1002/alz.12058.
    >> Share

  183. GEERTS H, Spiros A
    Learning from amyloid trials in Alzheimer's disease. A virtual patient analysis using a quantitative systems pharmacology approach.
    Alzheimers Dement. 2020 Apr 7. doi: 10.1002/alz.12082.
    >> Share

  184. CABALLERO MAA, Song Z, Rubinski A, Duering M, et al
    Age-dependent amyloid deposition is associated with white matter alterations in cognitively normal adults during the adult life span.
    Alzheimers Dement. 2020;16:651-661.
    >> Share

    March 2020

  185. Alzheimer's Disease Research Enterprise in the Era of COVID-19/SARS-CoV-2.
    Alzheimers Dement. 2020 Mar 22. doi: 10.1002/alz.12093.
    >> Share

  186. 2020 Alzheimer's disease facts and figures.
    Alzheimers Dement. 2020 Mar 10. doi: 10.1002/alz.12068.
    >> Share

  187. JANSSEN O, Vos SJB, Garcia-Negredo G, Tochel C, et al
    Real-world evidence in Alzheimer's disease: The ROADMAP Data Cube.
    Alzheimers Dement. 2020;16:461-471.
    >> Share

  188. LOWE VJ, Lundt ES, Albertson SM, Min HK, et al
    Tau-positron emission tomography correlates with neuropathology findings.
    Alzheimers Dement. 2020;16:561-571.
    >> Share

  189. PAPP KV, Buckley R, Mormino E, Maruff P, et al
    Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD.
    Alzheimers Dement. 2020;16:552-560.
    >> Share

    February 2020
  190. XIONG C, Luo J, Coble D, Agboola F, et al
    Complex interactions underlie racial disparity in the risk of developing Alzheimer's disease dementia.
    Alzheimers Dement. 2020 Feb 17. doi: 10.1002/alz.12060.
    >> Share

  191. SCHAFFERT J, LoBue C, White CL 3rd, Wilmoth K, et al
    Risk factors for earlier dementia onset in autopsy-confirmed Alzheimer's disease, mixed Alzheimer's with Lewy bodies, and pure Lewy body disease.
    Alzheimers Dement. 2020 Feb 11. doi: 10.1002/alz.12049.
    >> Share

  192. FRANZMEIER N, Koutsouleris N, Benzinger T, Goate A, et al
    Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's disease-informed machine-learning.
    Alzheimers Dement. 2020 Feb 11. doi: 10.1002/alz.12032.
    >> Share

  193. Bill Gates funds $10 million grant to Alzheimer's Association to fuel research for Alzheimer's treatment.
    Alzheimers Dement. 2020;16:384.
    >> Share

  194. ANTONELL A, Tort-Merino A, Rios J, Balasa M, et al
    Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias.
    Alzheimers Dement. 2020;16:262-272.
    >> Share

  195. ANGULO SL, Henzi T, Neymotin SA, Suarez MD, et al
    Amyloid pathology-produced unexpected modifications of calcium homeostasis in hippocampal subicular dendrites.
    Alzheimers Dement. 2020;16:251-261.
    >> Share

    January 2020
  196. HERRING WJ, Ceesay P, Snyder E, Bliwise D, et al
    Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial.
    Alzheimers Dement. 2020 Jan 15. doi: 10.1002/alz.12035.
    >> Share

  197. JIA L, Fu Y, Shen L, Zhang H, et al
    PSEN1, PSEN2, and APP mutations in 404 Chinese pedigrees with familial Alzheimer's disease.
    Alzheimers Dement. 2020;16:178-191.
    >> Share

  198. SNYDER PJ, Snyder HM, Bain LJ
    Retinal imaging think tank convened by the Alzheimer's Association to examine its promise in the early detection of Alzheimer's.
    Alzheimers Dement. 2020;16:244.
    >> Share

  199. ALBER J, Goldfarb D, Thompson LI, Arthur E, et al
    Developing retinal biomarkers for the earliest stages of Alzheimer's disease: What we know, what we don't, and how to move forward.
    Alzheimers Dement. 2020;16:229-243.
    >> Share

  200. PATHAK GA, Zhou Z, Silzer TK, Barber RC, et al
    Two-stage Bayesian GWAS of 9576 individuals identifies SNP regions that are targeted by miRNAs inversely expressed in Alzheimer's and cancer.
    Alzheimers Dement. 2020;16:162-177.
    >> Share

  201. ASCHENBRENNER AJ, James BD, McDade E, Wang G, et al
    Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN).
    Alzheimers Dement. 2020;16:219-228.
    >> Share

  202. LINARD M, Letenneur L, Garrigue I, Doize A, et al
    Interaction between APOE4 and herpes simplex virus type 1 in Alzheimer's disease.
    Alzheimers Dement. 2020;16:200-208.
    >> Share

  203. KAPLOW J, Vandijck M, Gray J, Kanekiyo M, et al
    Concordance of Lumipulse cerebrospinal fluid t-tau/Abeta42 ratio with amyloid PET status.
    Alzheimers Dement. 2020;16:144-152.
    >> Share

    December 2019
  204. ELAHI FM, Casaletto KB, La Joie R, Walters SM, et al
    Plasma biomarkers of astrocytic and neuronal dysfunction in early- and late-onset Alzheimer's disease.
    Alzheimers Dement. 2019 Dec 23. pii: S1552-5260(19)35373.
    >> Share

  205. SABBAGH M, Sadowsky C, Tousi B, Agronin ME, et al
    Effects of a combined transcranial magnetic stimulation (TMS) and cognitive training intervention in patients with Alzheimer's disease.
    Alzheimers Dement. 2019 Dec 23. pii: S1552-5260(19)35367.
    >> Share

    November 2019
  206. JANSSEN O, Vos SJB, Garcia-Negredo G, Tochel C, et al
    Real-world evidence in Alzheimer's disease: The ROADMAP Data Cube.
    Alzheimers Dement. 2019 Nov 27. pii: S1552-5260(19)35487.
    >> Share

  207. ANDREWS SJ, Goate A, Anstey KJ
    Association between alcohol consumption and Alzheimer's disease: A Mendelian randomization study.
    Alzheimers Dement. 2019 Nov 27. pii: S1552-5260(19)35486.
    >> Share

  208. GONZALEZ HM, Tarraf W, Fornage M, Gonzalez KA, et al
    A research framework for cognitive aging and Alzheimer's disease among diverse US Latinos: Design and implementation of the Hispanic Community Health Study/Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA).
    Alzheimers Dement. 2019 Nov 20. pii: S1552-5260(19)35362.
    >> Share

  209. TOLAR M, Abushakra S, Sabbagh M
    The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis.
    Alzheimers Dement. 2019 Nov 4. pii: S1552-5260(19)35450.
    >> Share

  210. Corrigendum to "AMYPAD Diagnostic and Patient Management Study: Rationale and design" [Alzheimer's & Dementia 2019;15:388-99].
    Alzheimers Dement. 2019;15:1505.
    >> Share

    October 2019
  211. ISAACSON RS, Hristov H, Saif N, Hackett K, et al
    Individualized clinical management of patients at risk for Alzheimer's dementia.
    Alzheimers Dement. 2019 Oct 31. pii: S1552-5260(19)35368.
    >> Share

  212. PULINA MV, Hopkins M, Haroutunian V, Greengard P, et al
    C99 selectively accumulates in vulnerable neurons in Alzheimer's disease.
    Alzheimers Dement. 2019 Oct 30. pii: S1552-5260(19)35370.
    >> Share

  213. OSSENKOPPELE R, Lyoo CH, Sudre CH, van Westen D, et al
    Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease.
    Alzheimers Dement. 2019 Oct 28. pii: S1552-5260(19)35375.
    >> Share

  214. BROSSERON F, Kolbe CC, Santarelli F, Carvalho S, et al
    Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study.
    Alzheimers Dement. 2019 Oct 17. pii: S1552-5260(19)35352.
    >> Share

  215. STOCKER H, Nabers A, Perna L, Mollers T, et al
    Prediction of Alzheimer's disease diagnosis within 14 years through Abeta misfolding in blood plasma compared to APOE4 status, and other risk factors.
    Alzheimers Dement. 2019 Oct 11. pii: S1552-5260(19)35349.
    >> Share

  216. GLEASON CE, Norton D, Zuelsdorff M, Benton SF, et al
    Association between enrollment factors and incident cognitive impairment in Blacks and Whites: Data from the Alzheimer's Disease Center.
    Alzheimers Dement. 2019 Oct 6. pii: S1552-5260(19)35138.
    >> Share

  217. OGINO E, Manly JJ, Schupf N, Mayeux R, et al
    Current and past leisure time physical activity in relation to risk of Alzheimer's disease in older adults.
    Alzheimers Dement. 2019 Oct 3. pii: S1552-5260(19)35136.
    >> Share

  218. EHRHARDT S, Porsteinsson AP, Munro CA, Rosenberg PB, et al
    Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial.
    Alzheimers Dement. 2019 Oct 3. pii: S1552-5260(19)35112.
    >> Share

    September 2019
  219. MCRAE-MCKEE K, Udeh-Momoh CT, Price G, Bajaj S, et al
    Perspective: Clinical relevance of the dichotomous classification of Alzheimer's disease biomarkers: Should there be a "gray zone"?
    Alzheimers Dement. 2019 Sep 26. pii: S1552-5260(19)35133.
    >> Share

  220. BLUE EE, Horimoto ARVR, Mukherjee S, Wijsman EM, et al
    Local ancestry at APOE modifies Alzheimer's disease risk in Caribbean Hispanics.
    Alzheimers Dement. 2019 Sep 25. pii: S1552-5260(19)35348.
    >> Share

  221. SCHAEFER KR, Noonan C, Mosley M, Smith J, et al
    Differences in service utilization at an urban tribal health organization before and after Alzheimer's disease or related dementia diagnosis: A cohort study.
    Alzheimers Dement. 2019 Sep 20. pii: S1552-5260(19)35111.
    >> Share

    August 2019
  222. MC ARDLE R, Galna B, Donaghy P, Thomas A, et al
    Do Alzheimer's and Lewy body disease have discrete pathological signatures of gait?
    Alzheimers Dement. 2019 Aug 30. pii: S1552-5260(19)35120.
    >> Share

  223. ELDADAH BA, Fazio EM, McLinden KA
    Lucidity in dementia: A perspective from the NIA.
    Alzheimers Dement. 2019;15:1104-1106.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016